# Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

> **NCT00366704** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 400 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** bifeprunox
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00366704
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2013-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366704, "Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00366704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*